TSE:4151Pharmaceuticals
Is Strong MRD Clearance With Ziftomenib Reshaping The Investment Case For Kyowa Kirin (TSE:4151)?
Kura Oncology and Kyowa Kirin recently reported encouraging long-term Phase 1/2 KOMET-007 results showing that investigational ziftomenib plus 7+3 chemotherapy produced high remission rates, deep molecular responses and a manageable safety profile in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia.
A distinctive feature of the data is the high rate of early, deep minimal residual disease negativity alongside low treatment-related mortality, highlighting the regimen’s potential to...